Pharmaceutical Market Europe • May 2025 • 45
APPOINTMENTS
Novo Nordisk
Ludovic Helfgott
Novo Nordisk has appointed Ludovic Helfgott as executive vice president, product and portfolio strategy. Helfgott, who also serves as president of the Novo Nordisk Haemophilia Foundation council, takes on his latest role after most recently serving as Novo’s executive vice president of rare disease. Prior to joining the company, Helfgott held the position of global vice president, cardiovascular, renal and metabolism at AstraZeneca. He held roles of increasing responsibility over more than a decade at AstraZeneca, more recently serving as global vice president, anti-thrombotics and country president, Spain. Earlier in his career, Helfgott worked for McKinsey & Company. His latest position includes commercial strategy, medical affairs and business development across all therapy areas.
FDA
Martin Makary
The US Food and Drug Administration (FDA) has appointed Martin Makary as commissioner of food and drugs. Makary previously worked at Johns Hopkins University (JHU) and JHU Medical School, where he was a surgical oncologist specialising in hepatobiliary and pancreatic surgery, and chief of islet transplant surgery.
VectorY Therapeutics
Olga Uspenskaya-Cadoz
VectorY Therapeutics has appointed Olga Uspenskaya-Cadoz as chief medical officer. Uspenskaya-Cadoz holds two decades of experience in neurology, gene therapy and clinical development. She joins VectorY from Eli Lilly, where she served as vice president, medical, gene therapy. She was also previously vice president of clinical development at Prevail Therapeutics.
Halda Therapatics
Eyal Attar
Halda Therapeutics has appointed Eyal Attar as chief medical officer. Attar has over 25 years of industry experience and was most recently chief medical officer of Vor Bio. Prior to this, he served as senior vice president and chief medical officer for Aprea Therapeutics, and held multiple positions in clinical development at Agios Pharmaceuticals.
Hansa Biopharma
Maria Törnsén
Hansa Biopharma has appointed Maria Törnsén as chief operating officer and president US. Törnsén has over 20 years of experience across global and US operations. She most recently served as president North America at Calliditas Therapeutics, and previously held leadership roles at Sarepta Therapeutics, Sanofi Genzyme and Shire.
Abivax
Dominik Höchli
Abivax has appointed Dominik Höchli as a member of its board of directors. Höchli brings over two decades of leadership experience in global biopharma to the role. He previously held multiple leadership positions at AbbVie/Abbott, serving as vice president of global marketing for immunology and later as head of global medical affairs.
Dark Blue Therapeutics
Edwin Moses
Dark Blue Therapeutics has appointed Edwin Moses as chairman of the board. Moses has more than 30 years of board level experience. He previously served as chief executive officer of Oxford Asymmetry International and Ablynx, and currently serves as chairman of the board of companies including NanoSyrinx, LabGenius and Avantium.
MOMA Therapeutics
Susan Pandya
MOMA Therapeutics has appointed Susan Pandya as an independent member of its board of directors. Pandya holds over 20 years of industry experience and currently serves as vice president, clinical development and global head of late-stage oncology at Servier Pharmaceuticals. Previously, she led the clinical development of the isocitrate dehydrogenase portfolio at Agios Pharmaceuticals.
Secarna Pharmaceuticals
Dario Vignali
Secarna Pharmaceuticals has appointed Dario Vignali as a member of its oncology-focused scientific advisory board. Vignali is chair and distinguished professor of immunology at the University of Pittsburgh School of Medicine, where he holds the Frank Dixon chair in cancer immunology. He also holds positions at the UPMC Hillman Cancer Center.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services